Filing Details

Accession Number:
0001209191-20-045095
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-08-05 16:14:33
Reporting Period:
2020-08-03
Accepted Time:
2020-08-05 16:14:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1550395 David Altshuler C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp, Global Research And Cso No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-08-03 2,330 $86.52 31,232 No 4 M Direct
Common Stock Disposition 2020-08-03 458 $276.84 30,774 No 4 S Direct
Common Stock Disposition 2020-08-03 1,167 $278.14 29,607 No 4 S Direct
Common Stock Disposition 2020-08-03 605 $279.19 29,002 No 4 S Direct
Common Stock Disposition 2020-08-03 100 $279.98 28,902 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-08-03 2,330 $0.00 2,330 $86.52
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,660 2027-02-02 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $276.84 (range $276.62 to $277.20).
  3. Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $278.14 (range $277.79 to $278.65).
  5. Open market sales reported on this line occurred at a weighted average price of $279.19 (range $278.86 to $279.62).
  6. The option vests in 16 quarterly installments from 02/03/2017.